Company Overview
General information about the GlaxoSmithKline company
GlaxoSmithKline (GSK) is a multinational pharmaceutical and healthcare company headquartered in Brentford, London. The company was formed in 2000 through the merger of British company Glaxo Wellcome and American company SmithKline Beecham. It is one of the largest pharmaceutical companies in the world and is focused on the research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products.
History:
The history of GlaxoSmithKline can be traced back to the establishment of two independent companies: Joseph Nathan and Co. in New Zealand in 1873 and Burroughs Wellcome & Company in the UK in 1880. In 1995, Glaxo Wellcome PLC was formed through the merger of Glaxo and Burroughs Wellcome. SmithKline Beecham PLC was formed in 1989 through the merger of SmithKline Beckman Corporation and Beecham Group PLC. In 2000, the two companies merged to form GlaxoSmithKline.
Products:
GSK's product portfolio includes prescription medicines, vaccines, and consumer healthcare products. Its prescription medicines cover a broad range of therapeutic areas, including respiratory, HIV, oncology, and neurosciences. The company also offers vaccines for diseases such as influenza, meningitis, and shingles. Its consumer healthcare products include over-the-counter medicines, oral care, nutrition, and skin health products.
Research and Development:
GSK has a strong focus on research and development (R&D) and invests heavily in this area. The company has R&D facilities in the UK, US, Belgium, and China, among others. Its R&D efforts are focused on discovering and developing new medicines and vaccines for a wide range of diseases and conditions. GSK collaborates with academic institutions, governments, and other industry partners to advance its research efforts.
Corporate Responsibility:
GSK is committed to operating ethically and responsibly, with a focus on sustainability and corporate social responsibility. The company has various initiatives in place to reduce its environmental impact and improve access to healthcare for underserved populations. It also has policies in place to ensure ethical business practices and compliance with laws and regulations.
Financials:
In 2020, GSK reported revenues of £34 billion and a net income of £5.5 billion. The company employs over 100,000 people globally and has a presence in over 150 countries. Its primary stock exchange listings are on the London Stock Exchange and the New York Stock Exchange.
Partnerships:
GSK has formed partnerships with various organizations to further its research and development efforts, expand its product portfolio, and improve access to healthcare. Some notable collaborations include:
- Joint ventures with Pfizer in the areas of consumer healthcare and HIV treatment
- Collaboration with Sanofi to develop a COVID-19 vaccine
- Partnership with Innoviva to develop respiratory treatments
- Collaboration with Vir Biotechnology to develop pandemic treatments
- Partnership with the Bill & Melinda Gates Foundation to develop vaccines for malaria and tuberculosis
Summary:
GlaxoSmithKline is a multinational pharmaceutical and healthcare company focused on research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products. It has a strong history and presence in the market, with a commitment to corporate responsibility and ethical business practices. The company has a diverse range of products and partnerships that contribute to its strong financial performance.
What is special about the GlaxoSmithKline company?
There are several key factors that make GlaxoSmithKline (GSK) a unique and special company:
1. Size and Scope: GSK is one of the largest pharmaceutical companies in the world, with operations in over 150 countries and a vast portfolio of products spanning prescription medicines, consumer healthcare, and vaccines.
2. History and Legacy: GSK has a rich history dating back to the 19th century, with the merger of GlaxoWellcome and SmithKline Beecham in 2000 solidifying its position as a major player in the healthcare industry.
3. Research and Development: Innovation and research are at the heart of GSK's business, with significant investments made in discovering and developing new medicines to meet unmet medical needs.
4. Commitment to Global Health: GSK's mission is to improve the quality of human life by enabling people to do more, feel better, and live longer. The company is dedicated to addressing global health challenges, such as infectious diseases and access to healthcare in developing countries.
5. Diverse Portfolio: GSK has a diverse portfolio of products, including market-leading brands such as Advair, Sensodyne, and Flonase. It also has a strong pipeline of potential new medicines and vaccines in various stages of development.
6. Corporate Responsibility: GSK is committed to conducting business responsibly and ethically, with a focus on sustainability, environmental stewardship, and improving access to healthcare for underserved populations.
7. Culture and Values: GSK prides itself on its diverse and inclusive workplace culture, guided by a set of core values that prioritize integrity, respect for people, and transparency.
Overall, GSK's size, history, focus on innovation and global health, diverse portfolio, commitment to corporate responsibility, and strong culture make it a unique and esteemed company in the pharmaceutical industry.
Interesting facts about the GlaxoSmithKline company
CiAgICAgICAgICAgIDxk aXYgc3R5bGU9J3dpZHRo OiAxMDAlOyBkaXNwbGF5 OiBmbGV4OyBqdXN0aWZ5 LWNvbnRlbnQ6IGNlbnRl cjsnPgogICAgICAgICAg ICAgICAgPGRpdiBzdHls ZT0nCiAgICAgICAgICAg ICAgICAgICAgZGlzcGxh eTogZmxleDsKICAgICAg ICAgICAgICAgICAgICBh bGlnbi1pdGVtczogY2Vu dGVyOwogICAgICAgICAg ICAgICAgICAgIGJhY2tn cm91bmQtY29sb3I6ICNm MGY0Zjg7CiAgICAgICAg ICAgICAgICAgICAgYm9y ZGVyOiAxcHggc29saWQg I2QxZTNmMDsKICAgICAg ICAgICAgICAgICAgICBi b3JkZXItcmFkaXVzOiAx MHB4OwogICAgICAgICAg ICAgICAgICAgIHBhZGRp bmc6IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg bWFyZ2luOiAyMHB4IDA7 CiAgICAgICAgICAgICAg ICAgICAgZm9udC1mYW1p bHk6ICJTZWdvZSBVSSIs IFJvYm90bywgc2Fucy1z ZXJpZjsKICAgICAgICAg ICAgICAgICAgICBib3gt c2hhZG93OiAwIDJweCA2 cHggcmdiYSgwLCAwLCAw LCAwLjA1KTsKICAgICAg ICAgICAgICAgICAgICBt YXgtd2lkdGg6IDkwMHB4 OwogICAgICAgICAgICAg ICAgICAgIHdpZHRoOiAx MDAlOyc+CgogICAgICAg ICAgICAgICAgICAgIDwh LS0gWVlZOiBJbnNlcnQg eW91ciBsb2dvIGltYWdl IGhlcmUgLS0+CiAgICAg ICAgICAgICAgICAgICAg PGltZyBzcmM9ImFzc2V0 cy9sb2dvcy9udWREMEw2 a3V4VjhEV2xVdEpCOC53 ZWJwIiBhbHQ9IkdsYXhv U21pdGhLbGluZSIgdGl0 bGU9IkdsYXhvU21pdGhL bGluZSIgY2xhc3M9Imlt Zy1mbHVpZCIgaGVpZ2h0 PTkwIHdpZHRoPTkwIGxv YWRpbmc9J2xhenknPgoK ICAgICAgICAgICAgICAg ICAgICA8ZGl2IHN0eWxl PSdmbGV4OiAxOyB0ZXh0 LWFsaWduOiBjZW50ZXI7 IG1hcmdpbi1sZWZ0OiA1 cHg7Jz4KICAgICAgICAg ICAgICAgICAgICAgICAg PHAgc3R5bGU9J2ZvbnQt c2l6ZTogMjZweDsgY29s b3I6ICMzMzM7IG1hcmdp bi1ib3R0b206IDE1cHg7 Jz4KICAgICAgICAgICAg ICAgICAgICAgICAgICAg IFdhbnQgdG8gcmVhZCBt b3JlIGFib3V0IEdsYXhv U21pdGhLbGluZT8KICAg ICAgICAgICAgICAgICAg ICAgICAgPC9wPgoKICAg ICAgICAgICAgICAgICAg ICAgICAgPGEgaHJlZj0n aW5kZXgucGhwP3BhZ2U9 c2lnbnVwJyBzdHlsZT0n CiAgICAgICAgICAgICAg ICAgICAgICAgICAgICBi YWNrZ3JvdW5kLWNvbG9y OiAjMDA3QkZGOwogICAg ICAgICAgICAgICAgICAg ICAgICAgICAgY29sb3I6 ICNmZmY7CiAgICAgICAg ICAgICAgICAgICAgICAg ICAgICBwYWRkaW5nOiAx MHB4IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg ICAgICAgICBib3JkZXIt cmFkaXVzOiA1cHg7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IG5v bmU7CiAgICAgICAgICAg ICAgICAgICAgICAgICAg ICBmb250LXdlaWdodDog Ym9sZDsKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG1hcmdpbi1yaWdo dDogMTBweDsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIHRyYW5zaXRp b246IGJhY2tncm91bmQt Y29sb3IgMC4zcyBlYXNl OycKICAgICAgICAgICAg ICAgICAgICAgICAgICAg IG9ubW91c2VvdmVyPSd0 aGlzLnN0eWxlLmJhY2tn cm91bmRDb2xvcj0iIzAw NTZiMyIKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG9ubW91c2VvdXQ9 J3RoaXMuc3R5bGUuYmFj a2dyb3VuZENvbG9yPSIj MDA3QkZGIj4KICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIFNpZ24gdXAg Zm9yIGZyZWUKICAgICAg ICAgICAgICAgICAgICAg ICAgPC9hPgoKICAgICAg ICAgICAgICAgICAgICAg ICAgPHNwYW4gc3R5bGU9 J21hcmdpbjogMCA4cHg7 IGNvbG9yOiAjNTU1Oyc+ b3I8L3NwYW4+CgogICAg ICAgICAgICAgICAgICAg ICAgICA8YSBocmVmPSdp bmRleC5waHA/cGFnZT1s b2dpbicgc3R5bGU9Jwog ICAgICAgICAgICAgICAg ICAgICAgICAgICAgY29s b3I6ICMwMDdCRkY7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IHVu ZGVybGluZTsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIGZvbnQtd2Vp Z2h0OiA1MDA7Jz4KICAg ICAgICAgICAgICAgICAg ICAgICAgICAgIGxvZyBp bgogICAgICAgICAgICAg ICAgICAgICAgICA8L2E+ CiAgICAgICAgICAgICAg ICAgICAgPC9kaXY+CiAg ICAgICAgICAgICAgICA8 L2Rpdj4KICAgICAgICAg ICAgPC9kaXY+CgogICAg ICAgICAgICA=
What is the GlaxoSmithKline company's primary line of business?
CiAgICAgICAgICAgIDxk aXYgc3R5bGU9J3dpZHRo OiAxMDAlOyBkaXNwbGF5 OiBmbGV4OyBqdXN0aWZ5 LWNvbnRlbnQ6IGNlbnRl cjsnPgogICAgICAgICAg ICAgICAgPGRpdiBzdHls ZT0nCiAgICAgICAgICAg ICAgICAgICAgZGlzcGxh eTogZmxleDsKICAgICAg ICAgICAgICAgICAgICBh bGlnbi1pdGVtczogY2Vu dGVyOwogICAgICAgICAg ICAgICAgICAgIGJhY2tn cm91bmQtY29sb3I6ICNm MGY0Zjg7CiAgICAgICAg ICAgICAgICAgICAgYm9y ZGVyOiAxcHggc29saWQg I2QxZTNmMDsKICAgICAg ICAgICAgICAgICAgICBi b3JkZXItcmFkaXVzOiAx MHB4OwogICAgICAgICAg ICAgICAgICAgIHBhZGRp bmc6IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg bWFyZ2luOiAyMHB4IDA7 CiAgICAgICAgICAgICAg ICAgICAgZm9udC1mYW1p bHk6ICJTZWdvZSBVSSIs IFJvYm90bywgc2Fucy1z ZXJpZjsKICAgICAgICAg ICAgICAgICAgICBib3gt c2hhZG93OiAwIDJweCA2 cHggcmdiYSgwLCAwLCAw LCAwLjA1KTsKICAgICAg ICAgICAgICAgICAgICBt YXgtd2lkdGg6IDkwMHB4 OwogICAgICAgICAgICAg ICAgICAgIHdpZHRoOiAx MDAlOyc+CgogICAgICAg ICAgICAgICAgICAgIDwh LS0gWVlZOiBJbnNlcnQg eW91ciBsb2dvIGltYWdl IGhlcmUgLS0+CiAgICAg ICAgICAgICAgICAgICAg PGltZyBzcmM9ImFzc2V0 cy9sb2dvcy9udWREMEw2 a3V4VjhEV2xVdEpCOC53 ZWJwIiBhbHQ9IkdsYXhv U21pdGhLbGluZSIgdGl0 bGU9IkdsYXhvU21pdGhL bGluZSIgY2xhc3M9Imlt Zy1mbHVpZCIgaGVpZ2h0 PTkwIHdpZHRoPTkwIGxv YWRpbmc9J2xhenknPgoK ICAgICAgICAgICAgICAg ICAgICA8ZGl2IHN0eWxl PSdmbGV4OiAxOyB0ZXh0 LWFsaWduOiBjZW50ZXI7 IG1hcmdpbi1sZWZ0OiA1 cHg7Jz4KICAgICAgICAg ICAgICAgICAgICAgICAg PHAgc3R5bGU9J2ZvbnQt c2l6ZTogMjZweDsgY29s b3I6ICMzMzM7IG1hcmdp bi1ib3R0b206IDE1cHg7 Jz4KICAgICAgICAgICAg ICAgICAgICAgICAgICAg IFdhbnQgdG8gcmVhZCBt b3JlIGFib3V0IEdsYXhv U21pdGhLbGluZT8KICAg ICAgICAgICAgICAgICAg ICAgICAgPC9wPgoKICAg ICAgICAgICAgICAgICAg ICAgICAgPGEgaHJlZj0n aW5kZXgucGhwP3BhZ2U9 c2lnbnVwJyBzdHlsZT0n CiAgICAgICAgICAgICAg ICAgICAgICAgICAgICBi YWNrZ3JvdW5kLWNvbG9y OiAjMDA3QkZGOwogICAg ICAgICAgICAgICAgICAg ICAgICAgICAgY29sb3I6 ICNmZmY7CiAgICAgICAg ICAgICAgICAgICAgICAg ICAgICBwYWRkaW5nOiAx MHB4IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg ICAgICAgICBib3JkZXIt cmFkaXVzOiA1cHg7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IG5v bmU7CiAgICAgICAgICAg ICAgICAgICAgICAgICAg ICBmb250LXdlaWdodDog Ym9sZDsKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG1hcmdpbi1yaWdo dDogMTBweDsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIHRyYW5zaXRp b246IGJhY2tncm91bmQt Y29sb3IgMC4zcyBlYXNl OycKICAgICAgICAgICAg ICAgICAgICAgICAgICAg IG9ubW91c2VvdmVyPSd0 aGlzLnN0eWxlLmJhY2tn cm91bmRDb2xvcj0iIzAw NTZiMyIKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG9ubW91c2VvdXQ9 J3RoaXMuc3R5bGUuYmFj a2dyb3VuZENvbG9yPSIj MDA3QkZGIj4KICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIFNpZ24gdXAg Zm9yIGZyZWUKICAgICAg ICAgICAgICAgICAgICAg ICAgPC9hPgoKICAgICAg ICAgICAgICAgICAgICAg ICAgPHNwYW4gc3R5bGU9 J21hcmdpbjogMCA4cHg7 IGNvbG9yOiAjNTU1Oyc+ b3I8L3NwYW4+CgogICAg ICAgICAgICAgICAgICAg ICAgICA8YSBocmVmPSdp bmRleC5waHA/cGFnZT1s b2dpbicgc3R5bGU9Jwog ICAgICAgICAgICAgICAg ICAgICAgICAgICAgY29s b3I6ICMwMDdCRkY7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IHVu ZGVybGluZTsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIGZvbnQtd2Vp Z2h0OiA1MDA7Jz4KICAg ICAgICAgICAgICAgICAg ICAgICAgICAgIGxvZyBp bgogICAgICAgICAgICAg ICAgICAgICAgICA8L2E+ CiAgICAgICAgICAgICAg ICAgICAgPC9kaXY+CiAg ICAgICAgICAgICAgICA8 L2Rpdj4KICAgICAgICAg ICAgPC9kaXY+CgogICAg ICAgICAgICA=
What is the market opportunity of the GlaxoSmithKline company?
CiAgICAgICAgICAgIDxk aXYgc3R5bGU9J3dpZHRo OiAxMDAlOyBkaXNwbGF5 OiBmbGV4OyBqdXN0aWZ5 LWNvbnRlbnQ6IGNlbnRl cjsnPgogICAgICAgICAg ICAgICAgPGRpdiBzdHls ZT0nCiAgICAgICAgICAg ICAgICAgICAgZGlzcGxh eTogZmxleDsKICAgICAg ICAgICAgICAgICAgICBh bGlnbi1pdGVtczogY2Vu dGVyOwogICAgICAgICAg ICAgICAgICAgIGJhY2tn cm91bmQtY29sb3I6ICNm MGY0Zjg7CiAgICAgICAg ICAgICAgICAgICAgYm9y ZGVyOiAxcHggc29saWQg I2QxZTNmMDsKICAgICAg ICAgICAgICAgICAgICBi b3JkZXItcmFkaXVzOiAx MHB4OwogICAgICAgICAg ICAgICAgICAgIHBhZGRp bmc6IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg bWFyZ2luOiAyMHB4IDA7 CiAgICAgICAgICAgICAg ICAgICAgZm9udC1mYW1p bHk6ICJTZWdvZSBVSSIs IFJvYm90bywgc2Fucy1z ZXJpZjsKICAgICAgICAg ICAgICAgICAgICBib3gt c2hhZG93OiAwIDJweCA2 cHggcmdiYSgwLCAwLCAw LCAwLjA1KTsKICAgICAg ICAgICAgICAgICAgICBt YXgtd2lkdGg6IDkwMHB4 OwogICAgICAgICAgICAg ICAgICAgIHdpZHRoOiAx MDAlOyc+CgogICAgICAg ICAgICAgICAgICAgIDwh LS0gWVlZOiBJbnNlcnQg eW91ciBsb2dvIGltYWdl IGhlcmUgLS0+CiAgICAg ICAgICAgICAgICAgICAg PGltZyBzcmM9ImFzc2V0 cy9sb2dvcy9udWREMEw2 a3V4VjhEV2xVdEpCOC53 ZWJwIiBhbHQ9IkdsYXhv U21pdGhLbGluZSIgdGl0 bGU9IkdsYXhvU21pdGhL bGluZSIgY2xhc3M9Imlt Zy1mbHVpZCIgaGVpZ2h0 PTkwIHdpZHRoPTkwIGxv YWRpbmc9J2xhenknPgoK ICAgICAgICAgICAgICAg ICAgICA8ZGl2IHN0eWxl PSdmbGV4OiAxOyB0ZXh0 LWFsaWduOiBjZW50ZXI7 IG1hcmdpbi1sZWZ0OiA1 cHg7Jz4KICAgICAgICAg ICAgICAgICAgICAgICAg PHAgc3R5bGU9J2ZvbnQt c2l6ZTogMjZweDsgY29s b3I6ICMzMzM7IG1hcmdp bi1ib3R0b206IDE1cHg7 Jz4KICAgICAgICAgICAg ICAgICAgICAgICAgICAg IFdhbnQgdG8gcmVhZCBt b3JlIGFib3V0IEdsYXhv U21pdGhLbGluZT8KICAg ICAgICAgICAgICAgICAg ICAgICAgPC9wPgoKICAg ICAgICAgICAgICAgICAg ICAgICAgPGEgaHJlZj0n aW5kZXgucGhwP3BhZ2U9 c2lnbnVwJyBzdHlsZT0n CiAgICAgICAgICAgICAg ICAgICAgICAgICAgICBi YWNrZ3JvdW5kLWNvbG9y OiAjMDA3QkZGOwogICAg ICAgICAgICAgICAgICAg ICAgICAgICAgY29sb3I6 ICNmZmY7CiAgICAgICAg ICAgICAgICAgICAgICAg ICAgICBwYWRkaW5nOiAx MHB4IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg ICAgICAgICBib3JkZXIt cmFkaXVzOiA1cHg7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IG5v bmU7CiAgICAgICAgICAg ICAgICAgICAgICAgICAg ICBmb250LXdlaWdodDog Ym9sZDsKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG1hcmdpbi1yaWdo dDogMTBweDsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIHRyYW5zaXRp b246IGJhY2tncm91bmQt Y29sb3IgMC4zcyBlYXNl OycKICAgICAgICAgICAg ICAgICAgICAgICAgICAg IG9ubW91c2VvdmVyPSd0 aGlzLnN0eWxlLmJhY2tn cm91bmRDb2xvcj0iIzAw NTZiMyIKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG9ubW91c2VvdXQ9 J3RoaXMuc3R5bGUuYmFj a2dyb3VuZENvbG9yPSIj MDA3QkZGIj4KICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIFNpZ24gdXAg Zm9yIGZyZWUKICAgICAg ICAgICAgICAgICAgICAg ICAgPC9hPgoKICAgICAg ICAgICAgICAgICAgICAg ICAgPHNwYW4gc3R5bGU9 J21hcmdpbjogMCA4cHg7 IGNvbG9yOiAjNTU1Oyc+ b3I8L3NwYW4+CgogICAg ICAgICAgICAgICAgICAg ICAgICA8YSBocmVmPSdp bmRleC5waHA/cGFnZT1s b2dpbicgc3R5bGU9Jwog ICAgICAgICAgICAgICAg ICAgICAgICAgICAgY29s b3I6ICMwMDdCRkY7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IHVu ZGVybGluZTsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIGZvbnQtd2Vp Z2h0OiA1MDA7Jz4KICAg ICAgICAgICAgICAgICAg ICAgICAgICAgIGxvZyBp bgogICAgICAgICAgICAg ICAgICAgICAgICA8L2E+ CiAgICAgICAgICAgICAg ICAgICAgPC9kaXY+CiAg ICAgICAgICAgICAgICA8 L2Rpdj4KICAgICAgICAg ICAgPC9kaXY+CgogICAg ICAgICAgICA=
SWOT analysis of the GlaxoSmithKline company
CiAgICAgICAgICAgIDxk aXYgc3R5bGU9J3dpZHRo OiAxMDAlOyBkaXNwbGF5 OiBmbGV4OyBqdXN0aWZ5 LWNvbnRlbnQ6IGNlbnRl cjsnPgogICAgICAgICAg ICAgICAgPGRpdiBzdHls ZT0nCiAgICAgICAgICAg ICAgICAgICAgZGlzcGxh eTogZmxleDsKICAgICAg ICAgICAgICAgICAgICBh bGlnbi1pdGVtczogY2Vu dGVyOwogICAgICAgICAg ICAgICAgICAgIGJhY2tn cm91bmQtY29sb3I6ICNm MGY0Zjg7CiAgICAgICAg ICAgICAgICAgICAgYm9y ZGVyOiAxcHggc29saWQg I2QxZTNmMDsKICAgICAg ICAgICAgICAgICAgICBi b3JkZXItcmFkaXVzOiAx MHB4OwogICAgICAgICAg ICAgICAgICAgIHBhZGRp bmc6IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg bWFyZ2luOiAyMHB4IDA7 CiAgICAgICAgICAgICAg ICAgICAgZm9udC1mYW1p bHk6ICJTZWdvZSBVSSIs IFJvYm90bywgc2Fucy1z ZXJpZjsKICAgICAgICAg ICAgICAgICAgICBib3gt c2hhZG93OiAwIDJweCA2 cHggcmdiYSgwLCAwLCAw LCAwLjA1KTsKICAgICAg ICAgICAgICAgICAgICBt YXgtd2lkdGg6IDkwMHB4 OwogICAgICAgICAgICAg ICAgICAgIHdpZHRoOiAx MDAlOyc+CgogICAgICAg ICAgICAgICAgICAgIDwh LS0gWVlZOiBJbnNlcnQg eW91ciBsb2dvIGltYWdl IGhlcmUgLS0+CiAgICAg ICAgICAgICAgICAgICAg PGltZyBzcmM9ImFzc2V0 cy9sb2dvcy9udWREMEw2 a3V4VjhEV2xVdEpCOC53 ZWJwIiBhbHQ9IkdsYXhv U21pdGhLbGluZSIgdGl0 bGU9IkdsYXhvU21pdGhL bGluZSIgY2xhc3M9Imlt Zy1mbHVpZCIgaGVpZ2h0 PTkwIHdpZHRoPTkwIGxv YWRpbmc9J2xhenknPgoK ICAgICAgICAgICAgICAg ICAgICA8ZGl2IHN0eWxl PSdmbGV4OiAxOyB0ZXh0 LWFsaWduOiBjZW50ZXI7 IG1hcmdpbi1sZWZ0OiA1 cHg7Jz4KICAgICAgICAg ICAgICAgICAgICAgICAg PHAgc3R5bGU9J2ZvbnQt c2l6ZTogMjZweDsgY29s b3I6ICMzMzM7IG1hcmdp bi1ib3R0b206IDE1cHg7 Jz4KICAgICAgICAgICAg ICAgICAgICAgICAgICAg IFdhbnQgdG8gcmVhZCBt b3JlIGFib3V0IEdsYXhv U21pdGhLbGluZT8KICAg ICAgICAgICAgICAgICAg ICAgICAgPC9wPgoKICAg ICAgICAgICAgICAgICAg ICAgICAgPGEgaHJlZj0n aW5kZXgucGhwP3BhZ2U9 c2lnbnVwJyBzdHlsZT0n CiAgICAgICAgICAgICAg ICAgICAgICAgICAgICBi YWNrZ3JvdW5kLWNvbG9y OiAjMDA3QkZGOwogICAg ICAgICAgICAgICAgICAg ICAgICAgICAgY29sb3I6 ICNmZmY7CiAgICAgICAg ICAgICAgICAgICAgICAg ICAgICBwYWRkaW5nOiAx MHB4IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg ICAgICAgICBib3JkZXIt cmFkaXVzOiA1cHg7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IG5v bmU7CiAgICAgICAgICAg ICAgICAgICAgICAgICAg ICBmb250LXdlaWdodDog Ym9sZDsKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG1hcmdpbi1yaWdo dDogMTBweDsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIHRyYW5zaXRp b246IGJhY2tncm91bmQt Y29sb3IgMC4zcyBlYXNl OycKICAgICAgICAgICAg ICAgICAgICAgICAgICAg IG9ubW91c2VvdmVyPSd0 aGlzLnN0eWxlLmJhY2tn cm91bmRDb2xvcj0iIzAw NTZiMyIKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG9ubW91c2VvdXQ9 J3RoaXMuc3R5bGUuYmFj a2dyb3VuZENvbG9yPSIj MDA3QkZGIj4KICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIFNpZ24gdXAg Zm9yIGZyZWUKICAgICAg ICAgICAgICAgICAgICAg ICAgPC9hPgoKICAgICAg ICAgICAgICAgICAgICAg ICAgPHNwYW4gc3R5bGU9 J21hcmdpbjogMCA4cHg7 IGNvbG9yOiAjNTU1Oyc+ b3I8L3NwYW4+CgogICAg ICAgICAgICAgICAgICAg ICAgICA8YSBocmVmPSdp bmRleC5waHA/cGFnZT1s b2dpbicgc3R5bGU9Jwog ICAgICAgICAgICAgICAg ICAgICAgICAgICAgY29s b3I6ICMwMDdCRkY7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IHVu ZGVybGluZTsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIGZvbnQtd2Vp Z2h0OiA1MDA7Jz4KICAg ICAgICAgICAgICAgICAg ICAgICAgICAgIGxvZyBp bgogICAgICAgICAgICAg ICAgICAgICAgICA8L2E+ CiAgICAgICAgICAgICAg ICAgICAgPC9kaXY+CiAg ICAgICAgICAgICAgICA8 L2Rpdj4KICAgICAgICAg ICAgPC9kaXY+CgogICAg ICAgICAgICA=
Porter's Five Forces analysis for the GlaxoSmithKline company
CiAgICAgICAgICAgIDxk aXYgc3R5bGU9J3dpZHRo OiAxMDAlOyBkaXNwbGF5 OiBmbGV4OyBqdXN0aWZ5 LWNvbnRlbnQ6IGNlbnRl cjsnPgogICAgICAgICAg ICAgICAgPGRpdiBzdHls ZT0nCiAgICAgICAgICAg ICAgICAgICAgZGlzcGxh eTogZmxleDsKICAgICAg ICAgICAgICAgICAgICBh bGlnbi1pdGVtczogY2Vu dGVyOwogICAgICAgICAg ICAgICAgICAgIGJhY2tn cm91bmQtY29sb3I6ICNm MGY0Zjg7CiAgICAgICAg ICAgICAgICAgICAgYm9y ZGVyOiAxcHggc29saWQg I2QxZTNmMDsKICAgICAg ICAgICAgICAgICAgICBi b3JkZXItcmFkaXVzOiAx MHB4OwogICAgICAgICAg ICAgICAgICAgIHBhZGRp bmc6IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg bWFyZ2luOiAyMHB4IDA7 CiAgICAgICAgICAgICAg ICAgICAgZm9udC1mYW1p bHk6ICJTZWdvZSBVSSIs IFJvYm90bywgc2Fucy1z ZXJpZjsKICAgICAgICAg ICAgICAgICAgICBib3gt c2hhZG93OiAwIDJweCA2 cHggcmdiYSgwLCAwLCAw LCAwLjA1KTsKICAgICAg ICAgICAgICAgICAgICBt YXgtd2lkdGg6IDkwMHB4 OwogICAgICAgICAgICAg ICAgICAgIHdpZHRoOiAx MDAlOyc+CgogICAgICAg ICAgICAgICAgICAgIDwh LS0gWVlZOiBJbnNlcnQg eW91ciBsb2dvIGltYWdl IGhlcmUgLS0+CiAgICAg ICAgICAgICAgICAgICAg PGltZyBzcmM9ImFzc2V0 cy9sb2dvcy9udWREMEw2 a3V4VjhEV2xVdEpCOC53 ZWJwIiBhbHQ9IkdsYXhv U21pdGhLbGluZSIgdGl0 bGU9IkdsYXhvU21pdGhL bGluZSIgY2xhc3M9Imlt Zy1mbHVpZCIgaGVpZ2h0 PTkwIHdpZHRoPTkwIGxv YWRpbmc9J2xhenknPgoK ICAgICAgICAgICAgICAg ICAgICA8ZGl2IHN0eWxl PSdmbGV4OiAxOyB0ZXh0 LWFsaWduOiBjZW50ZXI7 IG1hcmdpbi1sZWZ0OiA1 cHg7Jz4KICAgICAgICAg ICAgICAgICAgICAgICAg PHAgc3R5bGU9J2ZvbnQt c2l6ZTogMjZweDsgY29s b3I6ICMzMzM7IG1hcmdp bi1ib3R0b206IDE1cHg7 Jz4KICAgICAgICAgICAg ICAgICAgICAgICAgICAg IFdhbnQgdG8gcmVhZCBt b3JlIGFib3V0IEdsYXhv U21pdGhLbGluZT8KICAg ICAgICAgICAgICAgICAg ICAgICAgPC9wPgoKICAg ICAgICAgICAgICAgICAg ICAgICAgPGEgaHJlZj0n aW5kZXgucGhwP3BhZ2U9 c2lnbnVwJyBzdHlsZT0n CiAgICAgICAgICAgICAg ICAgICAgICAgICAgICBi YWNrZ3JvdW5kLWNvbG9y OiAjMDA3QkZGOwogICAg ICAgICAgICAgICAgICAg ICAgICAgICAgY29sb3I6 ICNmZmY7CiAgICAgICAg ICAgICAgICAgICAgICAg ICAgICBwYWRkaW5nOiAx MHB4IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg ICAgICAgICBib3JkZXIt cmFkaXVzOiA1cHg7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IG5v bmU7CiAgICAgICAgICAg ICAgICAgICAgICAgICAg ICBmb250LXdlaWdodDog Ym9sZDsKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG1hcmdpbi1yaWdo dDogMTBweDsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIHRyYW5zaXRp b246IGJhY2tncm91bmQt Y29sb3IgMC4zcyBlYXNl OycKICAgICAgICAgICAg ICAgICAgICAgICAgICAg IG9ubW91c2VvdmVyPSd0 aGlzLnN0eWxlLmJhY2tn cm91bmRDb2xvcj0iIzAw NTZiMyIKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG9ubW91c2VvdXQ9 J3RoaXMuc3R5bGUuYmFj a2dyb3VuZENvbG9yPSIj MDA3QkZGIj4KICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIFNpZ24gdXAg Zm9yIGZyZWUKICAgICAg ICAgICAgICAgICAgICAg ICAgPC9hPgoKICAgICAg ICAgICAgICAgICAgICAg ICAgPHNwYW4gc3R5bGU9 J21hcmdpbjogMCA4cHg7 IGNvbG9yOiAjNTU1Oyc+ b3I8L3NwYW4+CgogICAg ICAgICAgICAgICAgICAg ICAgICA8YSBocmVmPSdp bmRleC5waHA/cGFnZT1s b2dpbicgc3R5bGU9Jwog ICAgICAgICAgICAgICAg ICAgICAgICAgICAgY29s b3I6ICMwMDdCRkY7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IHVu ZGVybGluZTsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIGZvbnQtd2Vp Z2h0OiA1MDA7Jz4KICAg ICAgICAgICAgICAgICAg ICAgICAgICAgIGxvZyBp bgogICAgICAgICAgICAg ICAgICAgICAgICA8L2E+ CiAgICAgICAgICAgICAg ICAgICAgPC9kaXY+CiAg ICAgICAgICAgICAgICA8 L2Rpdj4KICAgICAgICAg ICAgPC9kaXY+CgogICAg ICAgICAgICA=
What is the GlaxoSmithKline company's business model?
CiAgICAgICAgICAgIDxk aXYgc3R5bGU9J3dpZHRo OiAxMDAlOyBkaXNwbGF5 OiBmbGV4OyBqdXN0aWZ5 LWNvbnRlbnQ6IGNlbnRl cjsnPgogICAgICAgICAg ICAgICAgPGRpdiBzdHls ZT0nCiAgICAgICAgICAg ICAgICAgICAgZGlzcGxh eTogZmxleDsKICAgICAg ICAgICAgICAgICAgICBh bGlnbi1pdGVtczogY2Vu dGVyOwogICAgICAgICAg ICAgICAgICAgIGJhY2tn cm91bmQtY29sb3I6ICNm MGY0Zjg7CiAgICAgICAg ICAgICAgICAgICAgYm9y ZGVyOiAxcHggc29saWQg I2QxZTNmMDsKICAgICAg ICAgICAgICAgICAgICBi b3JkZXItcmFkaXVzOiAx MHB4OwogICAgICAgICAg ICAgICAgICAgIHBhZGRp bmc6IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg bWFyZ2luOiAyMHB4IDA7 CiAgICAgICAgICAgICAg ICAgICAgZm9udC1mYW1p bHk6ICJTZWdvZSBVSSIs IFJvYm90bywgc2Fucy1z ZXJpZjsKICAgICAgICAg ICAgICAgICAgICBib3gt c2hhZG93OiAwIDJweCA2 cHggcmdiYSgwLCAwLCAw LCAwLjA1KTsKICAgICAg ICAgICAgICAgICAgICBt YXgtd2lkdGg6IDkwMHB4 OwogICAgICAgICAgICAg ICAgICAgIHdpZHRoOiAx MDAlOyc+CgogICAgICAg ICAgICAgICAgICAgIDwh LS0gWVlZOiBJbnNlcnQg eW91ciBsb2dvIGltYWdl IGhlcmUgLS0+CiAgICAg ICAgICAgICAgICAgICAg PGltZyBzcmM9ImFzc2V0 cy9sb2dvcy9udWREMEw2 a3V4VjhEV2xVdEpCOC53 ZWJwIiBhbHQ9IkdsYXhv U21pdGhLbGluZSIgdGl0 bGU9IkdsYXhvU21pdGhL bGluZSIgY2xhc3M9Imlt Zy1mbHVpZCIgaGVpZ2h0 PTkwIHdpZHRoPTkwIGxv YWRpbmc9J2xhenknPgoK ICAgICAgICAgICAgICAg ICAgICA8ZGl2IHN0eWxl PSdmbGV4OiAxOyB0ZXh0 LWFsaWduOiBjZW50ZXI7 IG1hcmdpbi1sZWZ0OiA1 cHg7Jz4KICAgICAgICAg ICAgICAgICAgICAgICAg PHAgc3R5bGU9J2ZvbnQt c2l6ZTogMjZweDsgY29s b3I6ICMzMzM7IG1hcmdp bi1ib3R0b206IDE1cHg7 Jz4KICAgICAgICAgICAg ICAgICAgICAgICAgICAg IFdhbnQgdG8gcmVhZCBt b3JlIGFib3V0IEdsYXhv U21pdGhLbGluZT8KICAg ICAgICAgICAgICAgICAg ICAgICAgPC9wPgoKICAg ICAgICAgICAgICAgICAg ICAgICAgPGEgaHJlZj0n aW5kZXgucGhwP3BhZ2U9 c2lnbnVwJyBzdHlsZT0n CiAgICAgICAgICAgICAg ICAgICAgICAgICAgICBi YWNrZ3JvdW5kLWNvbG9y OiAjMDA3QkZGOwogICAg ICAgICAgICAgICAgICAg ICAgICAgICAgY29sb3I6 ICNmZmY7CiAgICAgICAg ICAgICAgICAgICAgICAg ICAgICBwYWRkaW5nOiAx MHB4IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg ICAgICAgICBib3JkZXIt cmFkaXVzOiA1cHg7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IG5v bmU7CiAgICAgICAgICAg ICAgICAgICAgICAgICAg ICBmb250LXdlaWdodDog Ym9sZDsKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG1hcmdpbi1yaWdo dDogMTBweDsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIHRyYW5zaXRp b246IGJhY2tncm91bmQt Y29sb3IgMC4zcyBlYXNl OycKICAgICAgICAgICAg ICAgICAgICAgICAgICAg IG9ubW91c2VvdmVyPSd0 aGlzLnN0eWxlLmJhY2tn cm91bmRDb2xvcj0iIzAw NTZiMyIKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG9ubW91c2VvdXQ9 J3RoaXMuc3R5bGUuYmFj a2dyb3VuZENvbG9yPSIj MDA3QkZGIj4KICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIFNpZ24gdXAg Zm9yIGZyZWUKICAgICAg ICAgICAgICAgICAgICAg ICAgPC9hPgoKICAgICAg ICAgICAgICAgICAgICAg ICAgPHNwYW4gc3R5bGU9 J21hcmdpbjogMCA4cHg7 IGNvbG9yOiAjNTU1Oyc+ b3I8L3NwYW4+CgogICAg ICAgICAgICAgICAgICAg ICAgICA8YSBocmVmPSdp bmRleC5waHA/cGFnZT1s b2dpbicgc3R5bGU9Jwog ICAgICAgICAgICAgICAg ICAgICAgICAgICAgY29s b3I6ICMwMDdCRkY7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IHVu ZGVybGluZTsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIGZvbnQtd2Vp Z2h0OiA1MDA7Jz4KICAg ICAgICAgICAgICAgICAg ICAgICAgICAgIGxvZyBp bgogICAgICAgICAgICAg ICAgICAgICAgICA8L2E+ CiAgICAgICAgICAgICAg ICAgICAgPC9kaXY+CiAg ICAgICAgICAgICAgICA8 L2Rpdj4KICAgICAgICAg ICAgPC9kaXY+CgogICAg ICAgICAgICA=
What is the GlaxoSmithKline company's unique selling proposition?
CiAgICAgICAgICAgIDxk aXYgc3R5bGU9J3dpZHRo OiAxMDAlOyBkaXNwbGF5 OiBmbGV4OyBqdXN0aWZ5 LWNvbnRlbnQ6IGNlbnRl cjsnPgogICAgICAgICAg ICAgICAgPGRpdiBzdHls ZT0nCiAgICAgICAgICAg ICAgICAgICAgZGlzcGxh eTogZmxleDsKICAgICAg ICAgICAgICAgICAgICBh bGlnbi1pdGVtczogY2Vu dGVyOwogICAgICAgICAg ICAgICAgICAgIGJhY2tn cm91bmQtY29sb3I6ICNm MGY0Zjg7CiAgICAgICAg ICAgICAgICAgICAgYm9y ZGVyOiAxcHggc29saWQg I2QxZTNmMDsKICAgICAg ICAgICAgICAgICAgICBi b3JkZXItcmFkaXVzOiAx MHB4OwogICAgICAgICAg ICAgICAgICAgIHBhZGRp bmc6IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg bWFyZ2luOiAyMHB4IDA7 CiAgICAgICAgICAgICAg ICAgICAgZm9udC1mYW1p bHk6ICJTZWdvZSBVSSIs IFJvYm90bywgc2Fucy1z ZXJpZjsKICAgICAgICAg ICAgICAgICAgICBib3gt c2hhZG93OiAwIDJweCA2 cHggcmdiYSgwLCAwLCAw LCAwLjA1KTsKICAgICAg ICAgICAgICAgICAgICBt YXgtd2lkdGg6IDkwMHB4 OwogICAgICAgICAgICAg ICAgICAgIHdpZHRoOiAx MDAlOyc+CgogICAgICAg ICAgICAgICAgICAgIDwh LS0gWVlZOiBJbnNlcnQg eW91ciBsb2dvIGltYWdl IGhlcmUgLS0+CiAgICAg ICAgICAgICAgICAgICAg PGltZyBzcmM9ImFzc2V0 cy9sb2dvcy9udWREMEw2 a3V4VjhEV2xVdEpCOC53 ZWJwIiBhbHQ9IkdsYXhv U21pdGhLbGluZSIgdGl0 bGU9IkdsYXhvU21pdGhL bGluZSIgY2xhc3M9Imlt Zy1mbHVpZCIgaGVpZ2h0 PTkwIHdpZHRoPTkwIGxv YWRpbmc9J2xhenknPgoK ICAgICAgICAgICAgICAg ICAgICA8ZGl2IHN0eWxl PSdmbGV4OiAxOyB0ZXh0 LWFsaWduOiBjZW50ZXI7 IG1hcmdpbi1sZWZ0OiA1 cHg7Jz4KICAgICAgICAg ICAgICAgICAgICAgICAg PHAgc3R5bGU9J2ZvbnQt c2l6ZTogMjZweDsgY29s b3I6ICMzMzM7IG1hcmdp bi1ib3R0b206IDE1cHg7 Jz4KICAgICAgICAgICAg ICAgICAgICAgICAgICAg IFdhbnQgdG8gcmVhZCBt b3JlIGFib3V0IEdsYXhv U21pdGhLbGluZT8KICAg ICAgICAgICAgICAgICAg ICAgICAgPC9wPgoKICAg ICAgICAgICAgICAgICAg ICAgICAgPGEgaHJlZj0n aW5kZXgucGhwP3BhZ2U9 c2lnbnVwJyBzdHlsZT0n CiAgICAgICAgICAgICAg ICAgICAgICAgICAgICBi YWNrZ3JvdW5kLWNvbG9y OiAjMDA3QkZGOwogICAg ICAgICAgICAgICAgICAg ICAgICAgICAgY29sb3I6 ICNmZmY7CiAgICAgICAg ICAgICAgICAgICAgICAg ICAgICBwYWRkaW5nOiAx MHB4IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg ICAgICAgICBib3JkZXIt cmFkaXVzOiA1cHg7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IG5v bmU7CiAgICAgICAgICAg ICAgICAgICAgICAgICAg ICBmb250LXdlaWdodDog Ym9sZDsKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG1hcmdpbi1yaWdo dDogMTBweDsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIHRyYW5zaXRp b246IGJhY2tncm91bmQt Y29sb3IgMC4zcyBlYXNl OycKICAgICAgICAgICAg ICAgICAgICAgICAgICAg IG9ubW91c2VvdmVyPSd0 aGlzLnN0eWxlLmJhY2tn cm91bmRDb2xvcj0iIzAw NTZiMyIKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG9ubW91c2VvdXQ9 J3RoaXMuc3R5bGUuYmFj a2dyb3VuZENvbG9yPSIj MDA3QkZGIj4KICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIFNpZ24gdXAg Zm9yIGZyZWUKICAgICAg ICAgICAgICAgICAgICAg ICAgPC9hPgoKICAgICAg ICAgICAgICAgICAgICAg ICAgPHNwYW4gc3R5bGU9 J21hcmdpbjogMCA4cHg7 IGNvbG9yOiAjNTU1Oyc+ b3I8L3NwYW4+CgogICAg ICAgICAgICAgICAgICAg ICAgICA8YSBocmVmPSdp bmRleC5waHA/cGFnZT1s b2dpbicgc3R5bGU9Jwog ICAgICAgICAgICAgICAg ICAgICAgICAgICAgY29s b3I6ICMwMDdCRkY7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IHVu ZGVybGluZTsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIGZvbnQtd2Vp Z2h0OiA1MDA7Jz4KICAg ICAgICAgICAgICAgICAg ICAgICAgICAgIGxvZyBp bgogICAgICAgICAgICAg ICAgICAgICAgICA8L2E+ CiAgICAgICAgICAgICAg ICAgICAgPC9kaXY+CiAg ICAgICAgICAgICAgICA8 L2Rpdj4KICAgICAgICAg ICAgPC9kaXY+CgogICAg ICAgICAgICA=
How does the GlaxoSmithKline company differentiate itself in the market?
CiAgICAgICAgICAgIDxk aXYgc3R5bGU9J3dpZHRo OiAxMDAlOyBkaXNwbGF5 OiBmbGV4OyBqdXN0aWZ5 LWNvbnRlbnQ6IGNlbnRl cjsnPgogICAgICAgICAg ICAgICAgPGRpdiBzdHls ZT0nCiAgICAgICAgICAg ICAgICAgICAgZGlzcGxh eTogZmxleDsKICAgICAg ICAgICAgICAgICAgICBh bGlnbi1pdGVtczogY2Vu dGVyOwogICAgICAgICAg ICAgICAgICAgIGJhY2tn cm91bmQtY29sb3I6ICNm MGY0Zjg7CiAgICAgICAg ICAgICAgICAgICAgYm9y ZGVyOiAxcHggc29saWQg I2QxZTNmMDsKICAgICAg ICAgICAgICAgICAgICBi b3JkZXItcmFkaXVzOiAx MHB4OwogICAgICAgICAg ICAgICAgICAgIHBhZGRp bmc6IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg bWFyZ2luOiAyMHB4IDA7 CiAgICAgICAgICAgICAg ICAgICAgZm9udC1mYW1p bHk6ICJTZWdvZSBVSSIs IFJvYm90bywgc2Fucy1z ZXJpZjsKICAgICAgICAg ICAgICAgICAgICBib3gt c2hhZG93OiAwIDJweCA2 cHggcmdiYSgwLCAwLCAw LCAwLjA1KTsKICAgICAg ICAgICAgICAgICAgICBt YXgtd2lkdGg6IDkwMHB4 OwogICAgICAgICAgICAg ICAgICAgIHdpZHRoOiAx MDAlOyc+CgogICAgICAg ICAgICAgICAgICAgIDwh LS0gWVlZOiBJbnNlcnQg eW91ciBsb2dvIGltYWdl IGhlcmUgLS0+CiAgICAg ICAgICAgICAgICAgICAg PGltZyBzcmM9ImFzc2V0 cy9sb2dvcy9udWREMEw2 a3V4VjhEV2xVdEpCOC53 ZWJwIiBhbHQ9IkdsYXhv U21pdGhLbGluZSIgdGl0 bGU9IkdsYXhvU21pdGhL bGluZSIgY2xhc3M9Imlt Zy1mbHVpZCIgaGVpZ2h0 PTkwIHdpZHRoPTkwIGxv YWRpbmc9J2xhenknPgoK ICAgICAgICAgICAgICAg ICAgICA8ZGl2IHN0eWxl PSdmbGV4OiAxOyB0ZXh0 LWFsaWduOiBjZW50ZXI7 IG1hcmdpbi1sZWZ0OiA1 cHg7Jz4KICAgICAgICAg ICAgICAgICAgICAgICAg PHAgc3R5bGU9J2ZvbnQt c2l6ZTogMjZweDsgY29s b3I6ICMzMzM7IG1hcmdp bi1ib3R0b206IDE1cHg7 Jz4KICAgICAgICAgICAg ICAgICAgICAgICAgICAg IFdhbnQgdG8gcmVhZCBt b3JlIGFib3V0IEdsYXhv U21pdGhLbGluZT8KICAg ICAgICAgICAgICAgICAg ICAgICAgPC9wPgoKICAg ICAgICAgICAgICAgICAg ICAgICAgPGEgaHJlZj0n aW5kZXgucGhwP3BhZ2U9 c2lnbnVwJyBzdHlsZT0n CiAgICAgICAgICAgICAg ICAgICAgICAgICAgICBi YWNrZ3JvdW5kLWNvbG9y OiAjMDA3QkZGOwogICAg ICAgICAgICAgICAgICAg ICAgICAgICAgY29sb3I6 ICNmZmY7CiAgICAgICAg ICAgICAgICAgICAgICAg ICAgICBwYWRkaW5nOiAx MHB4IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg ICAgICAgICBib3JkZXIt cmFkaXVzOiA1cHg7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IG5v bmU7CiAgICAgICAgICAg ICAgICAgICAgICAgICAg ICBmb250LXdlaWdodDog Ym9sZDsKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG1hcmdpbi1yaWdo dDogMTBweDsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIHRyYW5zaXRp b246IGJhY2tncm91bmQt Y29sb3IgMC4zcyBlYXNl OycKICAgICAgICAgICAg ICAgICAgICAgICAgICAg IG9ubW91c2VvdmVyPSd0 aGlzLnN0eWxlLmJhY2tn cm91bmRDb2xvcj0iIzAw NTZiMyIKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG9ubW91c2VvdXQ9 J3RoaXMuc3R5bGUuYmFj a2dyb3VuZENvbG9yPSIj MDA3QkZGIj4KICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIFNpZ24gdXAg Zm9yIGZyZWUKICAgICAg ICAgICAgICAgICAgICAg ICAgPC9hPgoKICAgICAg ICAgICAgICAgICAgICAg ICAgPHNwYW4gc3R5bGU9 J21hcmdpbjogMCA4cHg7 IGNvbG9yOiAjNTU1Oyc+ b3I8L3NwYW4+CgogICAg ICAgICAgICAgICAgICAg ICAgICA8YSBocmVmPSdp bmRleC5waHA/cGFnZT1s b2dpbicgc3R5bGU9Jwog ICAgICAgICAgICAgICAg ICAgICAgICAgICAgY29s b3I6ICMwMDdCRkY7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IHVu ZGVybGluZTsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIGZvbnQtd2Vp Z2h0OiA1MDA7Jz4KICAg ICAgICAgICAgICAgICAg ICAgICAgICAgIGxvZyBp bgogICAgICAgICAgICAg ICAgICAgICAgICA8L2E+ CiAgICAgICAgICAgICAg ICAgICAgPC9kaXY+CiAg ICAgICAgICAgICAgICA8 L2Rpdj4KICAgICAgICAg ICAgPC9kaXY+CgogICAg ICAgICAgICA=
What are the GlaxoSmithKline company's potential challenges in the industry?
CiAgICAgICAgICAgIDxk aXYgc3R5bGU9J3dpZHRo OiAxMDAlOyBkaXNwbGF5 OiBmbGV4OyBqdXN0aWZ5 LWNvbnRlbnQ6IGNlbnRl cjsnPgogICAgICAgICAg ICAgICAgPGRpdiBzdHls ZT0nCiAgICAgICAgICAg ICAgICAgICAgZGlzcGxh eTogZmxleDsKICAgICAg ICAgICAgICAgICAgICBh bGlnbi1pdGVtczogY2Vu dGVyOwogICAgICAgICAg ICAgICAgICAgIGJhY2tn cm91bmQtY29sb3I6ICNm MGY0Zjg7CiAgICAgICAg ICAgICAgICAgICAgYm9y ZGVyOiAxcHggc29saWQg I2QxZTNmMDsKICAgICAg ICAgICAgICAgICAgICBi b3JkZXItcmFkaXVzOiAx MHB4OwogICAgICAgICAg ICAgICAgICAgIHBhZGRp bmc6IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg bWFyZ2luOiAyMHB4IDA7 CiAgICAgICAgICAgICAg ICAgICAgZm9udC1mYW1p bHk6ICJTZWdvZSBVSSIs IFJvYm90bywgc2Fucy1z ZXJpZjsKICAgICAgICAg ICAgICAgICAgICBib3gt c2hhZG93OiAwIDJweCA2 cHggcmdiYSgwLCAwLCAw LCAwLjA1KTsKICAgICAg ICAgICAgICAgICAgICBt YXgtd2lkdGg6IDkwMHB4 OwogICAgICAgICAgICAg ICAgICAgIHdpZHRoOiAx MDAlOyc+CgogICAgICAg ICAgICAgICAgICAgIDwh LS0gWVlZOiBJbnNlcnQg eW91ciBsb2dvIGltYWdl IGhlcmUgLS0+CiAgICAg ICAgICAgICAgICAgICAg PGltZyBzcmM9ImFzc2V0 cy9sb2dvcy9udWREMEw2 a3V4VjhEV2xVdEpCOC53 ZWJwIiBhbHQ9IkdsYXhv U21pdGhLbGluZSIgdGl0 bGU9IkdsYXhvU21pdGhL bGluZSIgY2xhc3M9Imlt Zy1mbHVpZCIgaGVpZ2h0 PTkwIHdpZHRoPTkwIGxv YWRpbmc9J2xhenknPgoK ICAgICAgICAgICAgICAg ICAgICA8ZGl2IHN0eWxl PSdmbGV4OiAxOyB0ZXh0 LWFsaWduOiBjZW50ZXI7 IG1hcmdpbi1sZWZ0OiA1 cHg7Jz4KICAgICAgICAg ICAgICAgICAgICAgICAg PHAgc3R5bGU9J2ZvbnQt c2l6ZTogMjZweDsgY29s b3I6ICMzMzM7IG1hcmdp bi1ib3R0b206IDE1cHg7 Jz4KICAgICAgICAgICAg ICAgICAgICAgICAgICAg IFdhbnQgdG8gcmVhZCBt b3JlIGFib3V0IEdsYXhv U21pdGhLbGluZT8KICAg ICAgICAgICAgICAgICAg ICAgICAgPC9wPgoKICAg ICAgICAgICAgICAgICAg ICAgICAgPGEgaHJlZj0n aW5kZXgucGhwP3BhZ2U9 c2lnbnVwJyBzdHlsZT0n CiAgICAgICAgICAgICAg ICAgICAgICAgICAgICBi YWNrZ3JvdW5kLWNvbG9y OiAjMDA3QkZGOwogICAg ICAgICAgICAgICAgICAg ICAgICAgICAgY29sb3I6 ICNmZmY7CiAgICAgICAg ICAgICAgICAgICAgICAg ICAgICBwYWRkaW5nOiAx MHB4IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg ICAgICAgICBib3JkZXIt cmFkaXVzOiA1cHg7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IG5v bmU7CiAgICAgICAgICAg ICAgICAgICAgICAgICAg ICBmb250LXdlaWdodDog Ym9sZDsKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG1hcmdpbi1yaWdo dDogMTBweDsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIHRyYW5zaXRp b246IGJhY2tncm91bmQt Y29sb3IgMC4zcyBlYXNl OycKICAgICAgICAgICAg ICAgICAgICAgICAgICAg IG9ubW91c2VvdmVyPSd0 aGlzLnN0eWxlLmJhY2tn cm91bmRDb2xvcj0iIzAw NTZiMyIKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG9ubW91c2VvdXQ9 J3RoaXMuc3R5bGUuYmFj a2dyb3VuZENvbG9yPSIj MDA3QkZGIj4KICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIFNpZ24gdXAg Zm9yIGZyZWUKICAgICAg ICAgICAgICAgICAgICAg ICAgPC9hPgoKICAgICAg ICAgICAgICAgICAgICAg ICAgPHNwYW4gc3R5bGU9 J21hcmdpbjogMCA4cHg7 IGNvbG9yOiAjNTU1Oyc+ b3I8L3NwYW4+CgogICAg ICAgICAgICAgICAgICAg ICAgICA8YSBocmVmPSdp bmRleC5waHA/cGFnZT1s b2dpbicgc3R5bGU9Jwog ICAgICAgICAgICAgICAg ICAgICAgICAgICAgY29s b3I6ICMwMDdCRkY7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IHVu ZGVybGluZTsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIGZvbnQtd2Vp Z2h0OiA1MDA7Jz4KICAg ICAgICAgICAgICAgICAg ICAgICAgICAgIGxvZyBp bgogICAgICAgICAgICAg ICAgICAgICAgICA8L2E+ CiAgICAgICAgICAgICAg ICAgICAgPC9kaXY+CiAg ICAgICAgICAgICAgICA8 L2Rpdj4KICAgICAgICAg ICAgPC9kaXY+CgogICAg ICAgICAgICA=
What challenges did the GlaxoSmithKline company face in the recent years?
CiAgICAgICAgICAgIDxk aXYgc3R5bGU9J3dpZHRo OiAxMDAlOyBkaXNwbGF5 OiBmbGV4OyBqdXN0aWZ5 LWNvbnRlbnQ6IGNlbnRl cjsnPgogICAgICAgICAg ICAgICAgPGRpdiBzdHls ZT0nCiAgICAgICAgICAg ICAgICAgICAgZGlzcGxh eTogZmxleDsKICAgICAg ICAgICAgICAgICAgICBh bGlnbi1pdGVtczogY2Vu dGVyOwogICAgICAgICAg ICAgICAgICAgIGJhY2tn cm91bmQtY29sb3I6ICNm MGY0Zjg7CiAgICAgICAg ICAgICAgICAgICAgYm9y ZGVyOiAxcHggc29saWQg I2QxZTNmMDsKICAgICAg ICAgICAgICAgICAgICBi b3JkZXItcmFkaXVzOiAx MHB4OwogICAgICAgICAg ICAgICAgICAgIHBhZGRp bmc6IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg bWFyZ2luOiAyMHB4IDA7 CiAgICAgICAgICAgICAg ICAgICAgZm9udC1mYW1p bHk6ICJTZWdvZSBVSSIs IFJvYm90bywgc2Fucy1z ZXJpZjsKICAgICAgICAg ICAgICAgICAgICBib3gt c2hhZG93OiAwIDJweCA2 cHggcmdiYSgwLCAwLCAw LCAwLjA1KTsKICAgICAg ICAgICAgICAgICAgICBt YXgtd2lkdGg6IDkwMHB4 OwogICAgICAgICAgICAg ICAgICAgIHdpZHRoOiAx MDAlOyc+CgogICAgICAg ICAgICAgICAgICAgIDwh LS0gWVlZOiBJbnNlcnQg eW91ciBsb2dvIGltYWdl IGhlcmUgLS0+CiAgICAg ICAgICAgICAgICAgICAg PGltZyBzcmM9ImFzc2V0 cy9sb2dvcy9udWREMEw2 a3V4VjhEV2xVdEpCOC53 ZWJwIiBhbHQ9IkdsYXhv U21pdGhLbGluZSIgdGl0 bGU9IkdsYXhvU21pdGhL bGluZSIgY2xhc3M9Imlt Zy1mbHVpZCIgaGVpZ2h0 PTkwIHdpZHRoPTkwIGxv YWRpbmc9J2xhenknPgoK ICAgICAgICAgICAgICAg ICAgICA8ZGl2IHN0eWxl PSdmbGV4OiAxOyB0ZXh0 LWFsaWduOiBjZW50ZXI7 IG1hcmdpbi1sZWZ0OiA1 cHg7Jz4KICAgICAgICAg ICAgICAgICAgICAgICAg PHAgc3R5bGU9J2ZvbnQt c2l6ZTogMjZweDsgY29s b3I6ICMzMzM7IG1hcmdp bi1ib3R0b206IDE1cHg7 Jz4KICAgICAgICAgICAg ICAgICAgICAgICAgICAg IFdhbnQgdG8gcmVhZCBt b3JlIGFib3V0IEdsYXhv U21pdGhLbGluZT8KICAg ICAgICAgICAgICAgICAg ICAgICAgPC9wPgoKICAg ICAgICAgICAgICAgICAg ICAgICAgPGEgaHJlZj0n aW5kZXgucGhwP3BhZ2U9 c2lnbnVwJyBzdHlsZT0n CiAgICAgICAgICAgICAg ICAgICAgICAgICAgICBi YWNrZ3JvdW5kLWNvbG9y OiAjMDA3QkZGOwogICAg ICAgICAgICAgICAgICAg ICAgICAgICAgY29sb3I6 ICNmZmY7CiAgICAgICAg ICAgICAgICAgICAgICAg ICAgICBwYWRkaW5nOiAx MHB4IDIwcHg7CiAgICAg ICAgICAgICAgICAgICAg ICAgICAgICBib3JkZXIt cmFkaXVzOiA1cHg7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IG5v bmU7CiAgICAgICAgICAg ICAgICAgICAgICAgICAg ICBmb250LXdlaWdodDog Ym9sZDsKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG1hcmdpbi1yaWdo dDogMTBweDsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIHRyYW5zaXRp b246IGJhY2tncm91bmQt Y29sb3IgMC4zcyBlYXNl OycKICAgICAgICAgICAg ICAgICAgICAgICAgICAg IG9ubW91c2VvdmVyPSd0 aGlzLnN0eWxlLmJhY2tn cm91bmRDb2xvcj0iIzAw NTZiMyIKICAgICAgICAg ICAgICAgICAgICAgICAg ICAgIG9ubW91c2VvdXQ9 J3RoaXMuc3R5bGUuYmFj a2dyb3VuZENvbG9yPSIj MDA3QkZGIj4KICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIFNpZ24gdXAg Zm9yIGZyZWUKICAgICAg ICAgICAgICAgICAgICAg ICAgPC9hPgoKICAgICAg ICAgICAgICAgICAgICAg ICAgPHNwYW4gc3R5bGU9 J21hcmdpbjogMCA4cHg7 IGNvbG9yOiAjNTU1Oyc+ b3I8L3NwYW4+CgogICAg ICAgICAgICAgICAgICAg ICAgICA8YSBocmVmPSdp bmRleC5waHA/cGFnZT1s b2dpbicgc3R5bGU9Jwog ICAgICAgICAgICAgICAg ICAgICAgICAgICAgY29s b3I6ICMwMDdCRkY7CiAg ICAgICAgICAgICAgICAg ICAgICAgICAgICB0ZXh0 LWRlY29yYXRpb246IHVu ZGVybGluZTsKICAgICAg ICAgICAgICAgICAgICAg ICAgICAgIGZvbnQtd2Vp Z2h0OiA1MDA7Jz4KICAg ICAgICAgICAgICAgICAg ICAgICAgICAgIGxvZyBp bgogICAgICAgICAgICAg ICAgICAgICAgICA8L2E+ CiAgICAgICAgICAgICAg ICAgICAgPC9kaXY+CiAg ICAgICAgICAgICAgICA8 L2Rpdj4KICAgICAgICAg ICAgPC9kaXY+CgogICAg ICAgICAgICA=